Compare Genworth Financial Inc Common Stock (GNW) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genworth Financial Inc Common Stock vs Nuwellis Inc — how do they compare? Genworth Financial Inc Common Stock trades at $8.82 (market cap $3.36B), while Nuwellis Inc trades at $0.55 (market cap $2.00M). The key difference: Genworth Financial Inc Common Stock is far larger — about 1680× Nuwellis Inc's market cap, and Genworth Financial Inc Common Stock is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Genworth Financial Inc Common Stock for 0 Days and Nuwellis Inc for 27 Days on average.
| GNW | NUWE | |
|---|---|---|
Market Cap | $3.36B | $2.00M |
Volume | 3,333,156 | 172,259 |
Sector | Financials | Health |
52-Week High | $10.60 | $146.65 |
52-Week Low | $7.94 | $0.53 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $2.87B | -$1.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
NUWE trades at $0.621, down 7.35% today, with a bearish technical signal despite oversold RSI readings. The company shows revenue growth with 2026 revenue reaching $9M, but continues to post significant losses with a -125.63% net income margin. Recent positive developments include strong Aquadex console adoption and expanded pediatric footprint, though cash flow remains negative requiring ongoing financing.
The outlook remains challenging with persistent losses and negative cash flow offset by promising commercial momentum. Investment opportunity hinges on the company's ability to achieve profitability while risks include execution challenges and dependence on financing. Analyst sentiment is mixed with equal buy/hold ratings reflecting the high-risk, high-reward nature of this medical technology stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Genworth Financial Inc Common Stock
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
